A bidding war for Acadia Pharmaceuticals and Nuplazid is likely to ensue after buyout rumors last Friday. Great news for ACAD stock owners.
Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma
Acquisition predictions for 2017 that include VRX, GILD, AmEx, SPLK, & WFM being bought, and Takeda, Pfizer, Apple, IBM, and Kroger spending big.
In part 1 of a 2-part series David examines his top dividend stocks for 2017, which include GILD, AT&T, SBGL, PFE, and BP.
Four dividend stocks and two growth stocks to buy that will yield a $30,000 annual return or more on $250,000 over the next decade.
Watson’s partnership with Pfizer is more important for IBM stock and PFE stock than investors and the market seems to realize.
The IBB is rallying in response to President Trump’s big win, and we expect continued gains from biotech stocks like Pfizer Inc (NYSE:PFE), Celgene Corporation (NASDAQ:CELG), and ACADIA Pharmaceuticals Inc (NASDAQ:ACAD).